Advertisement

The Effect of a Sharp Increase in Estrogen Levels on Overactive Bladder Symptoms in Women Undergoing Ovulation Induction

      ABSTRACT

      Objective

      To assess the effect of a sharp increase in estrogen levels on overactive bladder (OAB) symptoms among women undergoing ovulation induction.

      Methods

      100 consecutive women (mean age 36.9 ± 5.2 years) who underwent IVF treatments, were prospectively enrolled. Three validated questionnaires on urinary urgency, urinary incontinence, and lower urinary tract symptoms were used to evaluate patient's OAB symptoms before ovulation induction (low estradiol level) and prior to ovum pickup (peak estradiol level).

      Results

      Of the 100 women, 49 reported OAB symptoms prior to ovulation induction (mean USIQ severity score 33) and 51 women were asymptomatic. Of the 49 symptomatic women, 44 (90%) remained symptomatic (mean USIQ severity score 34) and 5 women became asymptomatic through ovulation induction. Of the 51 asymptomatic women, 24 (47%) developed de novo OAB symptoms, while 27 women (53%) remained asymptomatic through ovulation induction. The mean peak estradiol level was significantly higher among women who remained asymptomatic in comparison to women with de novo OAB symptoms (2069 versus 1372 pg/ml; respectively). Moreover, in most (63%) women who remained asymptomatic, peak estradiol levels were higher than 1500 pg/ml, whereas in most (67%) women who became symptomatic, peak estradiol levels were lower than 1500 pg/ml.

      Conclusion

      A higher estradiol level appears to have a protective effect against the development of OAB symptoms during ovulation induction. Further, in most (63%) women who remained asymptomatic, peak estradiol levels were higher than 1500 pg/ml. This finding may suggest a threshold for estradiol activity in the lower urinary tract.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Urology
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Iosif S
        • Batra S
        • Ek A
        • et al.
        Estrogens receptors in the human female lower urinary tract.
        Am J Obstet Gynaecol. 1981; 141: 817-820
        • Wolf H
        • Wandt H
        • Jonat W
        Immunohistochemical evidence of estrogen and progesterone receptors in the female lower urinary tract and comparison with vagina.
        Gynecol Obstet Invest. 1991; 32: 227-231
        • Blakeman PJ
        • Hilton P
        • Bulmar JN
        Oestrogen and progesterone expression in the female lower urinary tract, with reference to oestrogen status.
        BJU Int. 2000; 86: 32-38
        • Gruber CJ
        • Tschugguel W
        • Schneeberger C
        • et al.
        Production and actions of estrogens.
        N Engl J Med. 2002; 346: 340-352
        • Alperin M
        • Burnett L
        • Lukacz E
        • et al.
        The mysteries of menopause and urogynecologic health: clinical and scientific gaps.
        Menopause. 2019; 26: 103-111
        • Hanna-Mitchell AT
        • Robinson D
        • Cardozo L
        • et al.
        Do we need to know more about the effects of hormones on lower urinary tract dysfunction? ICI-RS 2014.
        Neurourol Urodyn. 2016; 35: 299-303
        • Provence A
        • Hristov KL
        • Parajuli SP
        • et al.
        Regulation of guinea pig detrusor smooth muscle excitability by 17β-Estradiol: the role of large conductive voltage- and Ca2+- activated K+ channels.
        Plose One. 2015; 10e0141950
        • Hristov KL
        • Parajuli SP
        • Provence A
        • et al.
        Nongenomic modulation of the large conductance voltage- and Ca2+-activated K+ channels by estrogen: a novel regulatory mechanism in human detrusor smooth muscle.
        Physiol Rep. 2017; 5: e13351
        • Cody JD
        • Jacobs ML
        • Richardson K
        • et al.
        Oestrogen therapy for urinary incontinence in post-menopausal women.
        Cochrane Database Syst Rev. 2012; 10CD001405
        • Amir H
        • Barbash-Hazan S
        • Kalma Y
        • et al.
        Time-lapse imaging reveals delayed development of embryos carrying unbalanced chromosomal translocations.
        J Assist Reprod Genet. 2019; 36: 315-324
        • Lowenstein L
        • Rickey L
        • Kenton K
        • et al.
        Reliability and responsiveness of the Urgency Severity and Life Impact Questionnaire (USIQ).
        Int Urogynecol J. 2012; 23: 193-196
        • Diokno AC
        • Catipay JR
        • Steinert BW
        Office assessment of patient outcome of pharmacologic therapy for urge incontinence.
        Int Urogynecol J. 2002; 13: 334-338
        • Brookes ST
        • Donovan JL
        • Wright M
        • et al.
        A scored form of the Bristol FLUTS questionnaire: data from a randomized controlled trial of surgery for women with stress incontinence.
        Am J Obstet Gynecol. 2004; 191: 73-82
        • Haylen BT
        • de Ridder D
        • Freeman RM
        • et al.
        An International Urogynecological Association (IUGA)/International Continence Society (ICS) joint report on the terminology for female pelvic floor dysfunction.
        Neurourol Urodynam. 2010; 29: 4-20
        • Stewart WF
        • Van Rooyen JB
        • Cundiff GW
        • et al.
        Prevalence and burden of overactive bladder in the United States.
        World J Urol. 2003; 20: 327-336
        • Coyne KS
        • Wein A
        • Nicholson S
        • et al.
        Economic burden of urgency urinary incontinence in the United States: a systematic review.
        J Manag Care Pharm. 2014; 20: 130-140
        • Snedecor SJ
        Review of economic value drivers of the treatment of overactive bladder.
        Pharmacoeconomics. 2018; 36: 1083-1092
        • Chapple CR
        • Nazir J
        • Hakimi Z
        • et al.
        Persistence and adherence with Mirabegron versus Antimuscarinic agents in patients with overactive bladder: a retrospective observational study in UK clinical practice.
        Eur Urol. 2017; 72: 389-399
        • Gray SL
        • Anderson ML
        • Dublin S
        • et al.
        Cumulative use of strong anticholinergics and incident dementia: a prospective cohort study.
        JAMA Intern Med. 2015; 175: 401-407
        • Andre L
        • Gallini A
        • Montastruc F
        • et al.
        Association between anticholinergic (atropinic) drug exposure and cognitive function in longitudinal studies among individuals over 50 years old: a systematic review.
        Eur J Clin Pharmacol. 2019; ([Epub ahead of print])https://doi.org/10.1007/s00228-019-02744-8
        • Weber MA
        • Kleijn MH
        • Langendam M
        • et al.
        Local oestrogen for pelvic floor disorders: a systematic review.
        PLoS One. 2015; 10e0136265https://doi.org/10.1371/journal.pone.0136265